Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 85 Recruiting 67 Completed 12 Not yet recruiting 9 Terminated 7 Suspended 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

Educational Status 5 Interviews as Topic 4 Standard of Care 3 Methods 3 Early Intervention, Educational 3 Cisplatin 3 Blood Specimen Collection 3 pembrolizumab 2 Surveys and Questionnaires 2 Practice Guidelines as Topic 2 Nivolumab 2 Music Therapy 2 Magnetic Resonance Imaging 2 Gemcitabine 2 Counseling 2 zilucoplan 1 tislelizumab 1 somapacitan 1 sacituzumab govitecan 1 rozanolixizumab 1 oxycodone-acetaminophen 1 ibrutinib 1 futibatinib 1 fluorodopa F 18 1 erdafitinib 1 enzalutamide 1 enfortumab vedotin 1 dynorphin-converting endopeptidase 1 durvalumab 1 dalpiciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Enrolling by invitation × durvalumab × 90 days × Clear all

NCT05303532 2026-05-19

ROSY-D

AstraZeneca

Phase 3 Enrolling by invitation

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡